ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

32.02
OTC Markets
Prev Close 32.04
Day Low/High 32.00 / 32.12
52 Wk Low/High 25.25 / 36.82
Exchange OTC Markets
Shares Outstanding 5620.50B
Market Cap 180.08B
Div & Yield N.A. (N.A)

Latest News

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

J&J's Janssen Pharmaceuticals will oppose Florida's use of its drug in a Thursday execution.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of The August 7, 2017 Deadline In The Class Action Lawsuit Against Roche Holding AG

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of The August 7, 2017 Deadline In The Class Action Lawsuit Against Roche Holding AG

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Roche Holding AG ("Roche" or the "Company") (OTC: RHHBY) securities between March 2, 2017...

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche To Showcase Power Of Connected Lab At AACC 2017 Clinical Lab Expo

Roche To Showcase Power Of Connected Lab At AACC 2017 Clinical Lab Expo

- Concept amplifies impact of diagnostics to help improve patient management

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat

Roche sees 'mid-single' digit sales growth in second half.

Positive Phase III Results Of Genentech's Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In New England Journal Of Medicine

Positive Phase III Results Of Genentech's Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in adult patients with GCA, were published in the...

Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform

Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform

Accenture (NYSE: ACN) is collaborating with Roche (SIX: RO, ROG; OTCQX: RHHBY) to improve how diabetes care is managed and delivered through the development of a data-driven core analytics platform for Roche's digital...

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

- AVENIO Millisect System utilizes an automated, digitally assisted process to reliably and efficiently isolate clinically relevant cells for diagnostic testing

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Roche Holding AG To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Roche Holding AG To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from HAVEN 1, a Phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and...

ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Roche Holding AG To Contact The Firm

ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Roche Holding AG To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Roche Holding AG ("Roche" or the "Company") (Other OTC:RHHBY) of the August 7, 2017 deadline to seek the role of lead plaintiff in a...

Roche Expands Into App-Based Digital Health With mySugr Deal

Roche Expands Into App-Based Digital Health With mySugr Deal

Financial terms of the acquisition were not disclosed.

Roche Expands Harmony® Prenatal Test To Include 22q11.2 Deletion Testing

-- New test option will be available globally mid-2017 in the Harmony CE-IVD kit and through the test send-out service from Ariosa Diagnostics Inc.

Genentech's Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III...

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Roche Holding AG Shareholders And A Lead Plaintiff Deadline Of August 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Roche Holding AG (OTCMKTS: RHHBY) who purchased shares between March 2, 2017 and June 5, 2017.

Roche Receives FDA Approval For Fourth-generation HIV Combination Antigen-antibody Assay --allowing Detection Of Infection With High Sensitivity And Specificity

Elecsys® HIV combi PT assay demonstrates commitment to improving efficiency by aiding labs in consolidating testing with other routine immunoassays

New Data At EAN Show Genentech's Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new post-hoc analyses from the OCREVUS TM (ocrelizumab) Phase III clinical trial program in people with relapsing and primary...

FDA Approves RITUXAN HYCELA (Rituximab And Hyaluronidase Human) For Subcutaneous Injection In Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Roche Holding AG Shareholders And A Lead Plaintiff Deadline Of August 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Roche Holding AG (OTCMKTS:RHHBY) who purchased shares between March 2, 2017 and June 5, 2017.